Providing sorafenib following TACE stems from the finding that HCC recurrence after TACE may be caused by an increase in VEGF production, resulting in new vasculature formation in the residual tumor [40]. A summary of all the studies related to the utilization of TACE in the management of unresectable HCC is mentioned in Table 5. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.